FDA issues EUA for Pfizer, BioNTech COVID-19 vaccine

By Samantha Black, PhD, ScienceBoard editor in chief

December 12, 2020 -- The U.S. Food and Drug Administration (FDA) has issued an emergency use authorization (EUA) for the Pfizer-BioNTech COVID-19 vaccine. The move comes after the FDA's Vaccines and Related Biological Products Advisory Committee (VRBPAC) issued a positive recommendation for the vaccine.

The vaccine is authorized for the prevention COVID-19 caused by SARS-CoV-2 in individuals 16 years of age and older. The messenger RNA (mRNA)-based vaccine is administered in two doses given three weeks apart.

Clinical trial data indicated that the vaccine had an efficacy rate of 95%. The most commonly reported side effects, which typically lasted several days, were pain at the injection site, tiredness, headache, muscle pain, chills, joint pain, and fever.

"Today's action follows an open and transparent review process that included input from independent scientific and public health experts and a thorough evaluation by the agency's career scientists to ensure this vaccine met FDA's rigorous, scientific standards for safety, effectiveness, and manufacturing quality needed to support emergency use authorization," said Dr. Stephen Hahn, FDA commissioner.

The EUA, which is different from full FDA approval (licensure), will be effective until circumstances that justify the authorization of the emergency use of drugs and biologics for prevention and treatment of COVID-19 change. At this point the EUA may be revised or revoked if it is determined it no longer meets the statutory criteria for issuance.

During the December 10 VRBPAC meeting, the sponsors made it clear that they would continue collecting data for a period of two years post vaccination in all trial participants with the goal of eventually filing for full licensure with a biologics license application.

With the authorization, the companies can begin vaccine distribution in the U.S. The vaccine has already been given emergency approval in several countries, including the U.K. and Canada.

"With science guiding our decision-making, the available safety and effectiveness data support the authorization of the Pfizer-BioNTech COVID-19 vaccine because the vaccine's known and potential benefits clearly outweigh its known and potential risks," explained Dr. Peter Marks, PhD, director of the FDA's Center for Biologics Evaluation and Research.

Copyright © 2020 scienceboard.net
To access all The ScienceBoard content create a free account now:

Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.
I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.

Already have an account? Sign in here